ClinicalTrials.gg
CompletedNCT00500760Updated Oct 17, 2018Results posted

Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer

A Phase 2 interventional study of Cisplatin and Standard Fractionation Radiotherapy in Head and Neck Cancer and Squamous Cell Carcinoma, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing panitumumab in Head and Neck Neoplasms — 3 open to participants now, 3 under way, none of them phase 3. Panitumumab · Head and Neck Neoplasms.

Enrollment
2nd of 14
153 · median 43
Started
2007
with 3 others
Phase 2
8 of 14
1 open now
Registered
2nd of 14
by date
Lead sponsor
3 of 14
Amgen

Among the 14 studies testing panitumumab in Head and Neck Neoplasms, this one is the 2nd largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 2, and was the 2nd registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

3 of the 14 studies testing panitumumab in Head and Neck Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing panitumumab in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed. The study is investigating if the addition of a targeted therapy (panitumumab) can improve the efficacy of chemoradiation without adding unmanageable toxicity.

03

Conditions studied

  • Head and Neck Cancer
  • Squamous Cell Carcinoma

Keywords

  • Head and Neck Cancer
  • panitumumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Stage III or IVa-b (M0) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx
  • (ECOG) performance status of 0 or 1 (you must be well enough to receive chemoradiation therapy)
  • You must be at least 18 years of age
  • Your test results must show that your kidneys, liver and blood cells are working adequately and that, if you are female, you are not pregnant
  • You must have

Exclusion criteria

Exclusion Criteria:

  • Cancer of the nasopharynx, sinus, salivary gland or skin
  • History of another cancer (other than head and neck) unless treated with curative intent and with no evidence of disease for more than 3 years, with the exception of non-melanoma skin cancer or in situ cervical cancer
  • Previous treatment with anti-endothelial growth factor receptor (EGFr) antibody therapy or EGFr inhibitors
  • Previous treatment for head and neck cancer, with chemotherapy, surgery (except nodal sampling or ) or radiotherapy
  • cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within one year before you join the study
  • (pneumonia or respiratory decompensation) resulting in hospitalization within 6 months of study screening
  • History or evidence of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis)
  • Major surgery within 28 days of screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Panitumumab Plus Chemoradiation

    Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m\^2 and panitumumab 9 mg/kg on Days 1, 22 and 43.

    Drug: Cisplatin · Radiation: Standard Fractionation Radiotherapy · Drug: Panitumumab

  • Active comparator
    Chemoradiotherapy Alone

    Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m\^2 on Days 1, 22, and 43.

    Drug: Cisplatin · Radiation: Standard Fractionation Radiotherapy

Interventions

  • Administered intravenously (IV; in a vein)

  • RadiationStandard Fractionation Radiotherapy

    70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)

  • Administered intravenously

    Also known as: Vectibix®

06

What researchers measure

Primary outcomes

  1. Local Regional Control Rate at 2 Years

    In this study participants were considered to be in local regional control (LRC) if there was no evidence of active disease in the previously affected/irradiated head-and-neck area. LRC could be achieved at any time following completion of treatment unless disease progression in the local-regional area occurred or the participant received subsequent anti-tumor therapy. Local regional control rate is defined as the Kaplan-Meier (KM) estimate of the proportion of participants with local regional control.

    Time frame: 2 years

Secondary outcomes

  1. Local Regional Control Rate at 6 Months and 12 Months

    Participants were considered to be in local regional control (LRC) if there was no evidence of active disease in the previously affected/irradiated head-and-neck area. LRC could be achieved at any time following completion of treatment unless disease progression in the local-regional area occurred or the participant received subsequent anti-tumor therapy. Local regional control rate is defined as the Kaplan-Meier (KM) estimate of the proportion of participants with local regional control.

    Time frame: 6 months and 12 months

  2. Duration of Local-regional Control

    Duration of local regional control is calculated from the first day of any study treatment (radiotherapy, chemotherapy, or panitumumab) administration to the date of first local-regional failure or to death due to any cause (whichever occurs first). Local-regional failure includes persistent disease and local-regional recurrence of disease. Participants who did not meet the criteria for LRC recurrence after achieving a response by the analysis data cutoff date were censored at their last evaluable disease assessment date. Participants who never achieved LRC were considered to have a duration of 0.

    Time frame: From first dose up to 37 months

  3. Progression-Free Survival

    Progression-free survival time is defined as time from the first day of any study treatment to date of first progresive disease using a modified version of the World Health Organization (WHO) criteria or death. Progressive Disease is defined as at least a 25% increase in the size of index lesions or unequivocal progression of existing non-index lesions or the presence of one or more new lesions. Participants not meeting these criteria by the cutoff date were censored at their last evaluable disease assessment date.

    Time frame: From first dose date to 37 months

  4. Overall Survival

    Survival time is defined as time from the first day of any study treatment to date of death. Participants who had not died by the cutoff date were censored at their last contact date.

    Time frame: From first dose date up to 37 months

  5. Percentage of Participants With an Objective Response at 6 Months

    Objective response by 6 months is defined as a complete response or partial response based on central review of scans using a a modification of the WHO criteria during the first 6 months. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the size of index lesions with no progression in non-index lesions, or the disappearance of all index lesions and persistence of 1 or more non-index lesions not qualifying for either CR or progressive disease and no new lesions.

    Time frame: 6 months

  6. Percentage of Participants With a Complete Response at 6 Months

    Response assessment based on central review of scans using a a modification of the WHO criteria, during the first 6 months. Complete Response is defined as the disappearance of all index and non-index lesions and no new lesions.

    Time frame: 6 months

07

Results

Posted Aug 5, 2014

Participant flow

153 patients were enrolled with 89 patients on panitumumab plus chemoradiation arm, and 64 patients on chemoradiotherapy alone arm.

Participant flow — Overall Study
MilestonePanitumumab Plus ChemoradiationChemoradiotherapy Alone
Started8964
Received treatment8763
Completed4640
Not completed4324
Withdrew: Death3215
Withdrew: Withdrawal by subject57
Withdrew: Administrative decision20
Withdrew: Lost to follow-up30
Withdrew: Other12

Outcome measures

PrimaryLocal Regional Control Rate at 2 Years

In this study participants were considered to be in local regional control (LRC) if there was no evidence of active disease in the previously affected/irradiated head-and-neck area. LRC could be achieved at any time following completion of treatment unless disease progression in the local-regional area occurred or the participant received subsequent anti-tumor therapy. Local regional control rate is defined as the Kaplan-Meier (KM) estimate of the proportion of participants with local regional control.

Time frame:
2 years
Reported as:
Number · proportion of paticipants
Local Regional Control Rate at 2 Years
proportion of paticipantsPanitumumab Plus ChemoradiationChemoradiotherapy Alone
Local Regional Control Rate at 2 Years0.61 (0.50 to 0.71)0.68 (0.54 to 0.78)
Statistical analysis
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Difference in kaplan-meier estimate: -0.07 · 95% CI -0.23 to 0.09The difference between the treatment groups is calculated as panitumumab plus chemoradiation minus chemoradiotherapy alone.
SecondaryLocal Regional Control Rate at 6 Months and 12 Months

Participants were considered to be in local regional control (LRC) if there was no evidence of active disease in the previously affected/irradiated head-and-neck area. LRC could be achieved at any time following completion of treatment unless disease progression in the local-regional area occurred or the participant received subsequent anti-tumor therapy. Local regional control rate is defined as the Kaplan-Meier (KM) estimate of the proportion of participants with local regional control.

Time frame:
6 months and 12 months
Reported as:
Number · proportion of paticipants
Local Regional Control Rate at 6 Months and 12 Months
proportion of paticipantsPanitumumab Plus ChemoradiationChemoradiotherapy Alone
6 months0.70 (0.59 to 0.79)0.73 (0.60 to 0.83)
12 months0.66 (0.55 to 0.75)0.70 (0.56 to 0.80)
Statistical analysis
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Difference in kaplan-meier estimate: -0.03 · 95% CI -0.18 to 0.12The difference between the treatment groups is calculated as panitumumab plus chemoradiation minus chemoradiotherapy alone.
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Difference in kaplan-meier estimate: -0.03 · 95% CI -1.09 to 0.12The difference between the treatment groups is calculated as panitumumab plus chemoradiation minus chemoradiotherapy alone.
SecondaryDuration of Local-regional Control

Duration of local regional control is calculated from the first day of any study treatment (radiotherapy, chemotherapy, or panitumumab) administration to the date of first local-regional failure or to death due to any cause (whichever occurs first). Local-regional failure includes persistent disease and local-regional recurrence of disease. Participants who did not meet the criteria for LRC recurrence after achieving a response by the analysis data cutoff date were censored at their last evaluable disease assessment date. Participants who never achieved LRC were considered to have a duration of 0.

Time frame:
From first dose up to 37 months
Reported as:
Median · months
Duration of Local-regional Control
monthsPanitumumab Plus ChemoradiationChemoradiotherapy Alone
Duration of Local-regional Control33.7 (28.8 to NA)NA (NA to NA)
Statistical analysis
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Regression, Cox · p = 0.3106 · Hazard ratio (hr): 1.328 · 95% CI 0.767 to 2.299Hazard ratio is presented as panitumumab plus chemoradiation:chemoradiotherapy alone.
SecondaryProgression-Free Survival

Progression-free survival time is defined as time from the first day of any study treatment to date of first progresive disease using a modified version of the World Health Organization (WHO) criteria or death. Progressive Disease is defined as at least a 25% increase in the size of index lesions or unequivocal progression of existing non-index lesions or the presence of one or more new lesions. Participants not meeting these criteria by the cutoff date were censored at their last evaluable disease assessment date.

Time frame:
From first dose date to 37 months
Reported as:
Median · months
Progression-Free Survival
monthsPanitumumab Plus ChemoradiationChemoradiotherapy Alone
Progression-Free SurvivalNA (24.3 to NA)NA (25.6 to NA)
Statistical analysis
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Regression, Cox · p = 0.6069 · Hazard ratio (hr): 1.150 · 95% CI 0.675 to 1.961Hazard ratio is presented as panitumumab plus chemoradiation:chemoradiotherapy alone.
SecondaryOverall Survival

Survival time is defined as time from the first day of any study treatment to date of death. Participants who had not died by the cutoff date were censored at their last contact date.

Time frame:
From first dose date up to 37 months
Reported as:
Median · months
Overall Survival
monthsPanitumumab Plus ChemoradiationChemoradiotherapy Alone
Overall Survival33.7 (32.2 to NA)NA (34.6 to NA)
Statistical analysis
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Regression, Cox · p = 0.1223 · Hazard ratio (hr): 1.628 · 95% CI 0.877 to 3.019Hazard ratio is presented as panitumumab plus chemoradiation:chemoradiotherapy alone.
SecondaryPercentage of Participants With an Objective Response at 6 Months

Objective response by 6 months is defined as a complete response or partial response based on central review of scans using a a modification of the WHO criteria during the first 6 months. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the size of index lesions with no progression in non-index lesions, or the disappearance of all index lesions and persistence of 1 or more non-index lesions not qualifying for either CR or progressive disease and no new lesions.

Time frame:
6 months
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response at 6 Months
percentage of participantsPanitumumab Plus ChemoradiationChemoradiotherapy Alone
Percentage of Participants With an Objective Response at 6 Months71.26 (60.57 to 80.46)82.26 (70.47 to 90.80)
Statistical analysis
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Regression, Logistic · p = 0.1737 · Odds ratio (or): 0.535 · 95% CI 0.217 to 1.262The odds ratio is defined as the odds of having an overall response in the panitumumab plus chemoradiation arm relative to the odds in the chemoradiotherapy alone arm.
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Difference in rate: -10.99 · 95% CI -24.56 to 4.14Difference is presented as the rate in panitumumab plus chemoradiation arm minus the rate in chemoradiotherapy alone arm.
SecondaryPercentage of Participants With a Complete Response at 6 Months

Response assessment based on central review of scans using a a modification of the WHO criteria, during the first 6 months. Complete Response is defined as the disappearance of all index and non-index lesions and no new lesions.

Time frame:
6 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Response at 6 Months
percentage of participantsPanitumumab Plus ChemoradiationChemoradiotherapy Alone
Percentage of Participants With a Complete Response at 6 Months20.69 (12.75 to 30.71)19.35 (10.42 to 31.37)
Statistical analysis
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Regression, Logistic · p = 1.0000 · Odds ratio (or): 1.087 · 95% CI 0.448 to 2.712The odds ratio is defined as the odds of having a complete response in the panitumumab plus chemoradiation arm relative to the odds in the chemoradiotherapy alone arm.
  • Panitumumab Plus Chemoradiation vs Chemoradiotherapy Alone · Difference in rate: 1.33 · 95% CI -13.23 to 14.71Difference is presented as the rate in panitumumab plus chemoradiation arm minus the rate in chemoradiotherapy alone arm.

Adverse events

Collected over The median reporting period was around 82 days in the Panitumumab Plus Chemoradiation arm, and around 80 days in the Chemoradiotherapy Alone arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus Chemoradiation—37/87 (42.5%)87/87 (100%)
Chemotherapy Plus Radiotherapy—20/63 (31.7%)63/63 (100%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventPanitumumab Plus ChemoradiationChemotherapy Plus Radiotherapy
DysphagiaGastrointestinal disorders6/874/63
NauseaGastrointestinal disorders6/874/63
Mucosal inflammationGeneral disorders6/871/63
VomitingGastrointestinal disorders5/874/63
PyrexiaGeneral disorders5/871/63
Radiation skin injuryInjury, poisoning and procedural complications5/870/63
DehydrationMetabolism and nutrition disorders5/872/63
Renal failureRenal and urinary disorders0/873/63
General physical health deteriorationGeneral disorders3/871/63
PneumoniaInfections and infestations3/872/63
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPanitumumab Plus ChemoradiationChemotherapy Plus Radiotherapy
Radiation skin injuryInjury, poisoning and procedural complications58/8752/63
Mucosal inflammationGeneral disorders71/8745/63
DysphagiaGastrointestinal disorders55/8740/63
NauseaGastrointestinal disorders45/8736/63
Dry mouthGastrointestinal disorders41/8733/63
RashSkin and subcutaneous tissue disorders40/871/63
Weight decreasedInvestigations37/8728/63
DysgeusiaNervous system disorders21/8727/63
ConstipationGastrointestinal disorders34/8721/63
VomitingGastrointestinal disorders29/8721/63

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panitumumab Plus ChemoradiationChemoradiotherapy AloneTotal
Mean58.0 ± 8.456.6 ± 8.857.4 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus ChemoradiationChemoradiotherapy AloneTotal
Female13720
Male7657133
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Panitumumab Plus ChemoradiationChemoradiotherapy AloneTotal
White or Caucasian8255137
Black or African American011
Hispanic or Latino303
Asian4812
Radiotherapy delivery modality
Radiotherapy delivery modality(Participants)Panitumumab Plus ChemoradiationChemoradiotherapy AloneTotal
IMRT524294
3D-CRT352156
Missing213
Primary tumor site
Primary tumor site(Participants)Panitumumab Plus ChemoradiationChemoradiotherapy AloneTotal
Oropharynx/Larynx6841109
Oral Cavity/Hypopharynx212344
Nodal status
Nodal status(Participants)Panitumumab Plus ChemoradiationChemoradiotherapy AloneTotal
N012921
N+7755132
Tumor stage
Tumor stage(Participants)Panitumumab Plus ChemoradiationChemoradiotherapy AloneTotal
T1-36445109
T4251944
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Mesia R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15. PubMed 25596660 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2007 to primary completion in Mar 2011, 41 months.

Results were first posted in Aug 2014, 3 years 4 months after primary completion.

Of 44 industry-sponsored phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 41 months is above that.

Counting every sponsor, half of 260 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2007
First posted
Jul 13, 2007
StartActual
Oct 1, 2007
Primary completionActual
Mar 29, 2011
CompletionActual
Apr 26, 2011
Results first posted
Aug 5, 2014
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00500760
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 13, 2007
Start date
Oct 1, 2007
Primary completion
Mar 29, 2011
Completion
Apr 26, 2011
Results posted
Aug 5, 2014
Last update
Oct 17, 2018

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion